Write in a clean editor, then format for Chemical Biology & Drug Design in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Chemical Biology & Drug Design is a peer-reviewed journal published by Wiley, covering Computational Drug Discovery Methods, Synthesis and biological activity, Chemical Synthesis and Analysis.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Chemical Biology & Drug Design 12 (3): 45–58.
Formats any DOI in Chemical Biology & Drug Design style. No sign-up. |
| Publishes research in | Computational Drug Discovery Methods Synthesis and biological activity Chemical Synthesis and Analysis Synthesis and Biological Evaluation Click Chemistry and Applications |
| ISSN | 1747-0277 |
| Citation impact (2-yr) | 2.9 |
| h-index | 98 |
| i10-index | 2,035 |
| Total citations | 79,292 |
| Article processing charge | $3,550 |
| Top institutions publishing here | China Pharmaceutical University |
| Journal website | onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The suite of currently used drugs can be divided into two categories - traditional 'small molecule' drugs with typical molecular weights of <500 Da but with oral bioavailability, and much larger 'biologics' typically >5000 Da that are not orally bioavailable and need to be delivered via injection. Due to their small size, conventional small molecule…
Glycosaminoglycans (GAGs) are important complex carbohydrates that participate in many biological processes through the regulation of their various protein partners. Biochemical, structural biology and molecular modelling approaches have assisted in understanding the molecular basis of such interactions, creating an opportunity to capitalize on the large structural diversity of GAGs in the discovery of new drugs.…
The formation of well-ordered fibrillar protein deposits is common to a large group of amyloid-associated disorders. This group consists of several major human diseases such as Alzheimer's disease, Parkinson's disease, prion diseases, and type II diabetes. Currently, there is no approved therapeutic agent directed towards the formation of fibrillar assemblies, which have been recently shown…
Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset. Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biological effects or new class of compounds. It is also…
Structured-based drug design has traditionally relied on a single receptor structure as a target for docking and screening studies. However, it has become increasingly clear that in many cases where protein flexibility is an issue, it is critical to accurately model ligand-induced receptor movement in order to obtain high enrichment factors. We present a novel…
